121 related articles for article (PubMed ID: 21406340)
1. International pharmaceutical social risk regulation: An ethical perspective.
Gordon C
Acta Pharm; 2011 Mar; 61(1):15-23. PubMed ID: 21406340
[TBL] [Abstract][Full Text] [Related]
2. Regulatory challenges, reimbursement, and risk-benefit assessment.
Breckenridge A
Clin Pharmacol Ther; 2010 Aug; 88(2):153-4. PubMed ID: 20648030
[No Abstract] [Full Text] [Related]
3. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
4. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
5. Safe drugs and the cost of good intentions.
Eichler HG; Abadie E; Raine JM; Salmonson T
N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
[No Abstract] [Full Text] [Related]
6. The role and responsibility of industry in research.
Lasagna L
Dolentium Hominum; 1987; 4(2nd Yr. 1):56-9. PubMed ID: 11653199
[No Abstract] [Full Text] [Related]
7. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
Chodock R; Yolkut D; Connolly DR
Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
[TBL] [Abstract][Full Text] [Related]
8. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
Purnhagen KP
Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
[No Abstract] [Full Text] [Related]
9. RU-486: legal and policy issues confronting the Food and Drug Administration.
Muhl C
J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
[TBL] [Abstract][Full Text] [Related]
10. Ethical, social and legal implications of pharmacogenomics: a critical review.
Moldrup C
Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484
[TBL] [Abstract][Full Text] [Related]
11. The learned intermediary doctrine: past, present and future.
Alsobrook HB
Leg Med; 1994; ():269-80. PubMed ID: 7830482
[No Abstract] [Full Text] [Related]
12. Informed consent: Enforcing pharmaceutical companies' obligations abroad.
Lee SB
Health Hum Rights; 2010 Jun; 12(1):15-28. PubMed ID: 20930251
[TBL] [Abstract][Full Text] [Related]
13. Developing drugs for the developing world: an economic, legal, moral, and political dilemma.
Resnik DB
Dev World Bioeth; 2001 May; 1(1):11-32. PubMed ID: 12870505
[TBL] [Abstract][Full Text] [Related]
14. ICH: an exclusive club of drug regulatory agencies and drug companies imposing its rules on the rest of the world.
Prescrire Int; 2010 Aug; 19(108):183-6. PubMed ID: 20939460
[TBL] [Abstract][Full Text] [Related]
15. Policies and quality assurance in the pharmaceutical industry.
Shamoo AE
Account Res; 1991; 1(4):273-84. PubMed ID: 11651459
[No Abstract] [Full Text] [Related]
16. The pharmaceutical industry--to whom is it accountable?
Summers WK; Driscoll J; Orient JM
N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183883
[No Abstract] [Full Text] [Related]
17. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
18. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe.
Porter RJ; Baulac M; Nohria V
Epilepsy Res; 2010 May; 89(2-3):163-75. PubMed ID: 20347575
[TBL] [Abstract][Full Text] [Related]
19. Social policy and drug safety.
Tilson HH
Clin Geriatr Med; 1986 Feb; 2(1):165-80. PubMed ID: 3513933
[TBL] [Abstract][Full Text] [Related]
20. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
Grandinetti CA; Osborne SF
Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
[No Abstract] [Full Text] [Related]
[Next] [New Search]
